Phaseline

Companies › Abcentra

Abcentra: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Orticumab
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor
–Phase 2Acute Coronary SyndromesFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06927739OrticumabPhase 2Acute Coronary SyndromesCardiovascularFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Implicit Bioscience Nyrada AllRock Bio Merakris Therapeutics Zomagen Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.